1DROP, a life sciences startup developing and commercializing an easy to use laboratory quality, portable medical diagnostic testing platform has raised $4.25 million in Series A funding led by led by Christian Wildmoser (former partner CVC Capital Partners & Swiss Startup Group Investor). The round also included participation from private investors of the Swiss Startup Group including Dr. Hans-Peter Strebel (owner of On Your Marks), Beat Schillig (IFJ Institute for Young Entrepreneurs) and Jean-Philippe de Toledo(CEO of Pharmacie Principale).
How It Works
One drop of blood contains a massive amount of information, millions of cells, trillions of small molecules like proteins, nucleic acids and ions. 1Drop provides personalized health insights by easily measuring biomarkers from a tiny drop of blood immediately in front of the patient to produce diagnostic test results within 15 minutes. Through the integration of biochemical reagents directly on the microfluidic chips, 1DROP dramatically miniaturize biochemical reactions preserving valuable samples and reagents, increasing the sensitivity of tests, accelerating mass transport limited reactions, leading to a faster time to high-quality results.
1DROP’s innovative diagnostic solutions for multiplexed assays of proteins, nucleic acids and peptides serve as tools for the development of new therapies, disease research, and clinical diagnostic tests.
1DROP is currently working with three pharmaceutical partners to create companion diagnostic products for cardiology, autoimmune disease, and glucose metabolism drug candidates. 1DROP’s business model is to actively work with pharmaceutical, diagnostic and biomarker companies to develop more integrated solutions between diagnostics and therapeutics that improve the outcome for the individual patient.
1DROP Commercialization Plans
1DROP plans to use the Series A funding to expand research and development and to commercialize the portable medical diagnostics platform. In addition, the company plans to perform clinical studies to demonstrate the device’s suitability for near-patient use and to develop additional panels of tests.
1DROP plans to obtain the appropriate regulatory approvals and integrate diagnostic test results with electronic medical records (EMRs). Through the use of machine learning, 1DROP will establish patterns of disease evolution and clinical outcomes.